Cargando…

Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis

BACKGROUND: Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction. OBJECTIVES: Objectives are to evaluate the efficacy and safety of liraglutide 3.0 mg in patients with overweight and obesity irrespective of diabetic status. METHODS: We conducted an electronic database sea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Konwar, Mahanjit, Bose, Debdipta, Jaiswal, Sanjeet Kumar, Maurya, Mitesh kumar, Ravi, Renju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325632/ https://www.ncbi.nlm.nih.gov/pubmed/35936066 http://dx.doi.org/10.1155/2022/1201977

Ejemplares similares

Vitamin D deficiency in rheumatoid arthritis patients of India – a single-arm meta-analysis
por: Bose, Debdipta, et al.
Publicado: (2023)

Impact of sodium-glucose co-transporter 2 inhibitors on renal outcomes in patients of diabetes mellitus: A meta-analysis of landmark renal and cardiovascular outcome trials
por: Bose, Debdipta, et al.
Publicado: (2023)

Investigator-initiated studies: Challenges and solutions
por: Konwar, Mahanjit, et al.
Publicado: (2018)

Improvements in health‐related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity
por: Kolotkin, R. L., et al.
Publicado: (2017)

The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg
por: Mancini, Marcio C., et al.
Publicado: (2017)

Exposure–response analyses of liraglutide 3.0 mg for weight management
por: Wilding, J. P. H., et al.
Publicado: (2016)

The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients
por: Albaker, Waleed, et al.
Publicado: (2021)

Adherence to and Dropout from Liraglutide 3.0 mg Obesity Treatment in a Real-World Setting
por: Ko, Hae-Jin, et al.
Publicado: (2022)

Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis
por: Overgaard, Rune V., et al.
Publicado: (2016)

Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial
por: Garvey, W. Timothy, et al.
Publicado: (2020)

Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real‐world effectiveness study in Canada
por: Wharton, Sean, et al.
Publicado: (2020)

Marked weight loss on liraglutide 3.0 mg: Real‐life experience of a Swiss cohort with obesity
por: Santini, Sara, et al.
Publicado: (2022)

An evaluation of drug lag for new drugs approved by the Indian regulator relative to the United States, European Union, and Japanese regulatory agencies: A 15-year analysis (2004–2018)
por: Konwar, Mahanjit, et al.
Publicado: (2021)

Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada
por: Wharton, Sean, et al.
Publicado: (2019)

A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder
por: Allison, Kelly C., et al.
Publicado: (2022)

Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial
por: Wadden, Thomas A., et al.
Publicado: (2020)

Investigator preparedness for monitoring and audits
por: Ravi, Renju, et al.
Publicado: (2018)

Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management
por: Kolotkin, R. L., et al.
Publicado: (2016)

Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
por: Blackman, A, et al.
Publicado: (2016)

Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review
por: Deng, You, et al.
Publicado: (2022)

Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery
por: Rubio-Herrera, Miguel A., et al.
Publicado: (2023)

An audit of reporting of conflict of interest policies among three stakeholders in Indian biomedical journals
por: Bose, Debdipta, et al.
Publicado: (2020)

Real‐world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program
por: Wharton, Sean, et al.
Publicado: (2020)

Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post‐bariatric surgery
por: Wharton, Sean, et al.
Publicado: (2019)

Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery
por: Muratori, Fabrizio, et al.
Publicado: (2022)

Benefits of Liraglutide Treatment in Overweight and Obese Older Individuals With Prediabetes
por: Kim, Sun H., et al.
Publicado: (2013)

Early Weight Loss with Liraglutide 3.0 mg Predicts 1‐Year Weight Loss and is Associated with Improvements in Clinical Markers
por: Fujioka, Ken, et al.
Publicado: (2016)

Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials
por: O'Neil, Patrick M., et al.
Publicado: (2017)

Impact of dose‐escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model‐based approach
por: Papathanasiou, Theodoros, et al.
Publicado: (2020)

Improving Adherence to Weight‐Loss Medication (Liraglutide 3.0 mg) Using Mobile Phone Text Messaging and Healthcare Professional Support
por: Li, Ang, et al.
Publicado: (2020)

Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit
por: Tempia Valenta, Silvia, et al.
Publicado: (2023)

SAT-099 Liraglutide 3.0 mg as an Adjunct to Intensive Behavior Therapy in Individuals with Obesity: SCALE IBT 56-Week Randomized, Double-Blind, Placebo-Controlled Trial
por: Wadden, Thomas, et al.
Publicado: (2019)

Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials
por: Ard, J., et al.
Publicado: (2016)

MON-120 Effect of Weight Loss on Physical Function Measured by the 6-Minute Walking Distance Test in Individuals with Obesity: Results from the SCALE IBT Trial of Liraglutide 3.0 Mg
por: Rubino, Domenica, et al.
Publicado: (2019)

Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial
por: Papamargaritis, Dimitris, et al.
Publicado: (2020)

A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg
por: Seino, Yutaka, et al.
Publicado: (2022)

Liraglutide and the management of overweight and obesity in people with severe mental illness: qualitative sub-study
por: Barnard-Kelly, Katharine, et al.
Publicado: (2022)

The global initiative for asthma guidelines (2019): change in the recommendation for the management of mild asthma based on the SYGMA-2 trial – A critical appraisal
por: Rajan, Sujeet, et al.
Publicado: (2020)

SAT-097 Weight Loss With Liraglutide 3.0 Mg Versus Placebo For Individuals Who Adhere To The Trial Drug: A Secondary Analysis From SCALE IBT
por: Shaw Tronieri, Jena, et al.
Publicado: (2019)

Effects of liraglutide on gallbladder emptying: A randomized, placebo‐controlled trial in adults with overweight or obesity
por: Nexøe‐Larsen, Christina C., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_opk11do2rej0hi5boce4evppl1